{"id":"W2886184165","doi":"10.1158/1538-7445.am2018-ct182","title":"Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced <i>BRAF</i> V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Biomarker; CD8; Peripheral blood mononuclear cell; Internal medicine; Melanoma; Gastroenterology; Oncology; Cancer; Immunology; Cancer research; Immune system; Metastatic melanoma; Biology; MAPK/ERK pathway; Vemurafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005462877,0.0008778847,0.0009878235,0.000390179,0.0002977994,0.00080268,0.0006314736,0.000583087,0.008381127],"category_scores_gemma":[0.0005789489,0.0002730151,0.0008486608,0.0004080673,0.0003948115,0.0005636471,0.0002533092,0.002018831,0.001598153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008399628,"about_ca_system_score_gemma":0.001282136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008189966,"about_ca_topic_score_gemma":0.001672354,"domain_scores_codex":[0.9997684,0.00007671727,0.00002003776,0.0000474804,0.00005145698,0.00003590351],"domain_scores_gemma":[0.9995281,0.00005072849,0.0001253349,0.0000370507,0.00005590174,0.0002029134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4003691,0.02302349,0.02403768,0.001979299,0.001803996,0.0008987105,0.0003043897,0.002350632,0.2710705,0.0005580103,0.0395097,0.2340945],"study_design_scores_gemma":[0.326872,0.4859383,0.07849655,0.0001492468,0.002278031,0.002769044,0.000119999,0.00247215,0.07130628,0.0003170946,0.02917868,0.0001025987],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787048,0.004879747,0.0008412003,0.000896387,0.0002234859,0.001722174,0.007522123,0.0002230466,0.004986973],"genre_scores_gemma":[0.9714916,0.002431584,0.001762802,0.0009027717,0.0002708775,0.001457491,0.01479857,0.00005567538,0.00682854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008381127,"threshold_uncertainty_score":0.02803767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02519849176344363,"score_gpt":0.3281862477773377,"score_spread":0.3029877560138941,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}